Compounding in the United States: A Retrospective

Compounding is the art and science of preparing medications for an individual patient either by a pharmacist or under the supervision of a pharmacist, pursuant to an order from a licensed prescriber. The compounding pharmacist can combine individual ingredients in the exact strength and dosage form to meet a patient’s specific needs. This can be necessary if commercially available medication is inappropriate for a specific patient due to clinical reasons, such as allergies to dyes or other ingredients, or due to population factors, including newborns, children and the elderly. Sometimes the medication may be compounded due to a shortage of manufactured product.

Cover photo courtesy of Mierlo-Hout, www.mierlohout.nl
32 PDA Members Discuss Compounding Events’ Impact on Industry

The following is a discussion among PDA members about the impact of the pharmaceutical compounding problems that surfaced in 2012/2013 and the impact on industry. The discussion occurred during the Q&A following the opening plenary presentations at the 2013 PDA Aseptic Processing-Sterilization Conference in Chicago, Ill., June 20–21. This discussion is abridged for space considerations. The full transcript of the proceedings, including slides, is available at the PDA Bookstore, www.pda.org/bookstore.

33 Quality Metrics Conference Shapes PDA Agenda

Over 300 industry experts on drug product quality and manufacturing assembled to participate in breakout discussions and select the most important and useful quality metrics. The interactive sessions were set up to assist a PDA task force draft a points to consider report on pharmaceutical quality metrics, which PDA intends to submit to the U.S. FDA in December.

34 Solutions Available for Compounders

This issue’s infographic showcases PDA services that offer solutions for issues faced by those involved in sterile compounding.
PDA Responds to FDA’s Call for Quality Metrics Recommendations

PDA answered the U.S. FDA’s Center for Drug Evaluation and Research (CDER) call for help in identifying quality metrics that can be used for the Center’s new drug quality enforcement initiative by connecting people, science, and regulation.

Cover Art Illustrated by Katja Yount

Departments

News & Notes

6 “Universe” Speakers, PDA Europe Rally to Help Children
7 PDA Volunteer Leaders Speaking on cGMPs at INTERPHEX

People

8 PDA Volunteer Spotlight: Don Elinski
10 India Chapter Hones in on Quality, Sterility Assurance
11 PDA Pulse: PDA Connector a Top Resource for New Publications Info
12 Tools For Success: 5 Reasons Your Resume May Not Be Generating Interviews

Science

14 Science Snapshot: Biotechnology Advisory Board Pushes Robust Agenda
Journal Preview: Special January–February Issue Features Viral Clearance Conference Proceedings
Tech Trend: Thermal Validation, Mapping Deliver More with Less
Task Force Corner: Glass Handling Task Force Identifies Best Practices
Rate the PDA Letter Science Snapshot!
17 “Remember the Science” at PDA’s Annual Meeting
19 Contamination Control Science Targeting Sessile Biofilms
20 Viral and TSE Safety Remains Key Goal
21 Packaging Innovations Continue to Flourish

Regulation

36 Regulatory Snapshot: Interest Group Corner: GMP Links to Pharmacovigilance Interest Group Pushes for Greater Physician Role in the GMP Quality System
39 Drug Shortage Issue, Solutions Highlighted
42 Quality Culture: An Opportunity for Patient-Focused Paradigms

Voices of PDA

44 Chair’s Message
45 President’s Message: Reflections and Forecasts
46 Editor’s Message: PDA Makes the Connections!
Features

28  Metric Session Readout Reports Highlight Industry Views
We are presenting a modified transcript from the breakout session readouts during the closing plenary session of the 2013 PDA Pharmaceutical Quality Metrics Conference held Dec. 9–10 in Bethesda, Md. Here, Anil Sawant, PhD, Joyce Bloomfield, Glenn Wright and Sue Schniepp, who all served as facilitators for the conference’s breakout sessions, discuss participants’ selections of particular metrics and the reasons behind them.

34  PDA PtC ID’s Range of Useful Metrics
This issue’s infographic showcases recommended metrics developed and discussed during the 2013 PDA Pharmaceutical Quality Metrics Conference.
The Changing Landscape of Release Testing for Sterile Drug Products

Has the time finally arrived when parametric release and real-time release can be implemented for sterile drug products, even those manufactured in aseptic processes without a sterilization phase, perhaps ultimately leading to a parametric release-like program for aseptically processed products?

Cover Art Illustrated by Katja Yount

Departments

News & Notes

6 2014 PDA ANNUAL MEETING FDA Will Have Its Say
7 2014 PDA ANNUAL MEETING Got a Particular Interest? Attend a PDA Interest Group Meeting at Annual

People

8 Volunteer Spotlight: Harald Stahl
10 Delaware Valley Chapter Welcomes New Officers
11 PDA Pulse: PDA Members Willing to Relocate Abroad
12 2014 PDA ANNUAL MEETING Network with Fellow PDA Members
13 PDA Photostream: PDA Visitors
14 Tools for Success: You WILL Get Googled… Are You Afraid?

Science


18 2014 PDA ANNUAL MEETING Biotech Manufacturing Getting Smaller, Flexible
20 Industry Looks to Future of Drug Delivery Options
21 2014 PDA ANNUAL MEETING A Biosimilar By Any Other Name is Still a Biosimilar

Regulation

34 Regulatory Snapshot: RAQAB Follows Comprehensive Commenting Process
36 2014 PDA ANNUAL MEETING Qualifying Disinfection for Critical Environments and Cleanrooms
39 Knowledge Management: Integral to the Quality System
41 Is Your Packaging System Qualified?
42 Regulatory Briefs
43 The Changing Drug Supply Chain Regulatory Umbrella

Voices of PDA

44 2014 PDA ANNUAL MEETING Voices of the Board: Annual Meeting Embraces Innovations, New Opportunities
46 Editor’s Message: Unabashedly Proud of the 2014 Annual Meeting
Contents

Features

26 **2014PDA Innovations Offer Solutions for Vaccine Supply Limitations**
A variety of factors have caused shortages in the marketplace for vaccines, but outdated manufacturing processes and lack of characterization stand out as some of the most prevalent, if not correctable, factors. Regulators across the globe and manufacturers are searching for ways to stabilize vaccine supplies.

32 **2014 PDA Annual Meeting by the Numbers**
This issue’s infographic breaks down the 2014 PDA Annual Meeting, showing the percentage of topics addressed for attendees.
USP Looks at Future of Microbiology With New Standards

From a microbiological perspective, pharmaceutical products fall into two categories, nonsterile and sterile. For either category, manufacturers must eliminate or minimize potential health risks to patients related to microorganisms and the toxins they produce, while also maintaining product quality. Many contributing factors may affect the quality of a medicine or its ingredients, but microbial bioburden control and proper sterilization methods are critical considerations for the manufacturer throughout the product’s lifecycle.

Cover Art Illustrated by Katja Yount

Departments

News & Notes

6 PDA in the News
7 A World of Regulatory Experts Awaits You in Europe

People

8 PDA Volunteer Spotlight: Chuck Reed
10 PDA Japan Chapter Holds 20th Annual Meeting in Tokyo
12 PDA Photostream: PDA PIC/S Q7 Training; TRI; Joint Regulators/Industry QbD Workshop
15 PDA Pulse: Going Where No PDA Member Has Gone Before
16 Tools For Success: Making Yourself Understood: How to Improve Accent Issues Linked to Stress

Science

18 Science Snapshot: Planned TRs Focus on Packaging Quality;
Journal Preview: March–April Issue Offers Risk-Based Auditing Commentary;
Tech Trends: PDA TRI Installs Facility Monitoring System; Task Force Corner: TR-63 Offers a “Stepping Stone” for Industry
20 Protection of Protein-Based Drug Products is Vital
21 Keeping an Eye on Pharmaceutical Packaging’s Future
22 Parenteral Packaging Concerns for Biologics

Regulation

34 Regulatory Snapshot: RAQAB Update: RAQAB Quarterly Report Q1 2014
36 Preventing and Managing Drug Shortages
40 Illicit Acts Threaten the Global Supply Chain
42 Regulators, Industry, Embrace Changes in Oversight, Quality

Voices of PDA

44 Voices of the Board: PDA Supports Quality in Manufacturing Operations
46 How Should PDA Cover the Pharmacopoeias?
30 Industry, Regulators Meet to Drive QbD Implementation

Since the first QbD workshop held in 2009, industry and regulators have continued working together to advance implementation of QbD principles. In January, PDA Europe organized a workshop to address continued progress in this area at the EMA’s London headquarters. This workshop was co-chaired by Jean-Louis Robert, National Health Laboratory EP (Luxembourg) and Chair of the EMA Quality Working Party, and Georges France, Novartis, for the European Federation of Pharmaceutical Industry and Associations (EFPIA).

33 Pharmacopoeias: The European System

This infographic spotlights the European Pharmacopoeia and its governance structure.
Adapting Development Guidelines for Advanced Therapies

Traditional pharmaceutical manufacturing is very familiar to all of us. It is easy to picture the conventional setup whereby a company maintains a facility involving large batch manufacturing in an assembly line fashion, manages extensive supply chains and creates product with lengthy shelf lives.

Cover Art Illustrated by Katja Yount
Contents

Features

28 Developing an Effective Manufacturing Control Strategy for Cellular Therapy Products
Successful commercialization of a cellular therapy product requires the development of the best quality product to suit patient needs.

32 The State of Advanced Therapies
This issue’s infographic shows the number of approved advanced therapy products in Europe and the United States broken down by category.

PDA’s MISSION
To develop scientifically sound, practical technical information and resources to advance science and regulation for the pharmaceutical and biopharmaceutical industry through the expertise of our global membership

PDA’s VISION
To be the foremost global provider of science, technology, and regulatory information and education for the pharmaceutical and biopharmaceutical community

EXECUTIVE STAFF
Richard Johnson
President
Craig Elliott
CFO
Robert Dana
Sr. VP, TRI
David Hall
VP, Sales
Rich Levy, PhD
Sr. VP, Scientific & Regulatory Affairs
Wanda Neal
Sr. Vice President, Programs and Registration Services
Georg Roessling, PhD
Sr. VP, PDA Europe

PDA BOARD OF DIRECTORS

Chair: Harold Baseman
ValSource

Chair-Elect: Martin VanTrieste
Angen

Treasurer: Rebecca Devine, PhD
Elvins & Associates

Secretary: Michael Sadowski
Baxter Healthcare

Immm. Past Chair: Anders Vinther
Genentech

OFFICERS

Joyce Bloomfield
Merck

Jette Christensen
Novo Nordisk

Ian Elvins
Elvins & Associates

Gabriele Gori
Novartis

Junko Sasaki, Dainippan
Sumitomo Pharma

Christopher Smalley, PhD
Merck

Ursula Busse, PhD
Novartis

Veronique Davoust
Pfizer

John Finkbohner, PhD
MedImmune

Stephan Rönninger
Angen

Lisa Skeens, PhD
Hapira

Glenn Wright
Eli Lilly and Company
Drug Manufacturers Face More “How to Do” CMC/GMP Requirements in Europe

Pharmaceutical manufacturers increasingly are facing more detailed “how to do” requirements focusing on a widening scope of activities (e.g., distribution) in Europe as the European Union continues to upgrade CMC and GMP requirements.
Unprecedented EU Rule Changes Shake Industry

The rate of ongoing changes to European pharmaceutical legislation and guidance are at an unprecedented level. Many are likely to have a profound impact on the industry over the next five years and some will require significant investment.

PDA Letter Infographic: U.S. vs EU Process Val Guidelines

This issue’s infographic details some of the similarities and differences between European and U.S. process validation regulations.
Industry, FDA Still Wary of Supply Chain Security

Public confidence in pharmaceutical products has waned in recent years based on patient harm caused by adulteration, drug shortages and poor quality resulting in recalls. Along with concern for patient safety, pharmaceutical professionals at all levels within their organizations have become keenly aware of the potential for damage to the company brand by such incidents.

Cover photo courtesy of Jim Greipp of Pau Hana Productions for Custom Processing Services (www.customprocessingservices.com). This photo depicts the GMP blending suite with two all-stainless double-ribbon blenders at Custom Processing Services’ dedicated GMP facility in Reading, PA. As a CMO, CPS follows ICH Q7A and their API processing conforms to part 210/211 of CFR 21 from the U.S. FDA.

News & Notes

Over 30 Regulators Scheduled to Speak in September
FDA Acting Chief Scientist Ostroff to Speak at PDA/FDA JRC

People

Volunteer Spotlight: Edward Smith
Tails from the Trail: PDA President Travels Full Circle to Support Activities
Build Your Network: Attend the 2014 PDA/FDA JRC
Tools for Success: DIY Resume Writing Advice

Science

Science Snapshot
Meeting Preview: Interest Group Meeting Schedule
Journal Preview: July–August Issue Looks at Quality
Tech Trends: NASA Maps Out Knowledge Management Mission
Task Force Corner: How Clean is Your Manufacturing/Testing Space?
PDA Summer Reading
Is QbD Possible for Monoclonal Antibodies and Biologics?

Regulation

Regulatory Snapshot: RAQAB Update: RAQAB Quarterly Report Q2 2014—Health Authority Publications on Slower Pace in 2014
The Value of PDA Technical Reports
Have a Reg Change Headache? Take Two Aspirins and Attend the PDA/FDA JRC
ICH Q10 Expectations Climb: Are You Prepared?
Drug Shortage Issues Continue to Plague Industry
PDA at the Forefront of Meeting Temp Sensitive Challenges
PDA Comments: EU Annex 15 Revision

Voices of PDA

Voices of the Board: PDA Facilitates Understanding Of CMO Management and Quality Agreements
Editor’s Message: Summertime Reading, Storms Underway!
Features

36 **Outsourcing Management: Key Component of a QMS**
Regulatory agencies hold firms responsible for delivering high quality products that meet all established requirements and specifications. Suppliers and vendors (most recently referred to as “outsourced materials and services”) play a key role in meeting GMP mandates, and it is a firm’s responsibility to make sure vendors/suppliers are meeting specifications for the supplied materials, components, equipment and/or services.

40 **CMO Vet of 40+ FDA Inspections Discusses Reg Landscape**
Robert Darius, VP, Regional Quality Unit, GSK Biologicals, interviewed Joachim del Boca for his thoughts on FDA’s aseptic processing guidance, harmonization, regulatory inspections and the role of Quality Agreements. Joachim del Boca, VP of Regulatory Affairs and Quality Compliance at Vetter, a contract development and manufacturing organization, has 31 years in the industry and is a veteran of over 40 U.S. FDA regulatory inspections.

44 **Five Typical Mistakes Found in Quality Agreements**
This issue’s infographic highlights some typical mistakes found in Quality Agreements with CMOs.

---

**PDA’s Mission**
To develop scientifically sound, practical technical information and resources to advance science and regulation for the pharmaceutical and biopharmaceutical industry through the expertise of our global membership

**PDA’s Vision**
To be the foremost global provider of science, technology, and regulatory information and education for the pharmaceutical and biopharmaceutical community

---

**Executive Staff**

<table>
<thead>
<tr>
<th>Office</th>
<th>Name</th>
<th>Company/Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Richard Johnson</td>
<td>Merck</td>
</tr>
<tr>
<td>CFO</td>
<td>Craig Elliott</td>
<td></td>
</tr>
<tr>
<td>Sr. VP, TRI</td>
<td>Robert Dana</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>VP, Sales</td>
<td>David Hall</td>
<td>Novartis</td>
</tr>
<tr>
<td>Sr. VP, Scientific &amp; Regulatory Affairs</td>
<td>Rich Levy, PhD</td>
<td>Sanofi Pasteur</td>
</tr>
<tr>
<td>Sr. Vice President, Programs and Registration Services</td>
<td>Wanda Neal</td>
<td>Amgen</td>
</tr>
<tr>
<td>Sr. VP, PDA Europe</td>
<td>Georg Roessling, PhD</td>
<td>Pfizer</td>
</tr>
</tbody>
</table>

**PDA Board of Directors**

**Chair:** Harold Baseman, ValSource
**Chair-Elect:** Martin VanTrieste, Amgen
**Treasurer:** Rebecca Devine, PhD, Elvins & Associates
**Secretary:** Michael Sadowski, Baxter Healthcare
**Imm. Past Chair:** Anders Vinther, Sanofi Pasteur

**Directors**

- Joyce Bloomfield, Merck
- Ursula Busse, PhD, Novartis
- Jette Christensen, Nano Nordisk
- Veronique Davoust, Pfizer
- Ian Elvins, Elvins & Associates
- John Finkbohner, PhD, MedImmune
- Gabriele Gori, Novartis
- Stephan Rönninger, Angen
- Junko Sasaki, Dainippon Sumitomo Pharma
- Lisa Skeens, PhD, Hospira
- Christopher Smalley, PhD, Merck
- Glenn Wright, Eli Lilly and Company
Cover

26 Will a Shorebird Knot Up Bacterial Endotoxin Assay Supplies?

The remarkable red knot shorebird has one of the longest migrations of any bird—over 9,000 miles from the southern tip of South America to the Arctic. That’s 18,000 miles round trip. A long annual journey made possible by its many stops on South American and North American Atlantic shores.

Cover Art Illustrated by Katja Yount

Departments

News & Notes

6 U.S. Gov’t Registration for TRI Just Got Easier!
7 Make Your Voice Heard: Vote in the 2014 Board Elections

People

8 Volunteer Spotlight: Kim Waters
10 PDA’s Japan Chapter Ramps Up Activity in 2014
11 2014年日本PDA製薬学会はイベント・行事が目白押し
12 In Memory of Julius Z. Knapp
12 The Latest Advances in Industry Available at the Click of a Mouse
14 PDA Photostream: 2014 Parenteral Manufacturing Conference

Science

16 Science Snapshot: Using the Lessons of the Past to Build Tomorrow; Journal Preview: September–October Issue Offers Pharmaceutical Microbiology Content
17 Emerging Perspectives on Use of Plant Isolates
18 Considerations When Moving to Rapid Methods
21 Endotoxin: 50+ Years of Advancements and Mysteries

Regulation

36 Regulatory Snapshot: Quality Culture Survey to Guide PDA Metrics Conference
39 New Rule, Guidance Impact Development of Drug Delivery
41 Quality Metrics: The Next Frontier
42 PDA Comments: Seeking Additional Clarification on Analytical Methods

Voices of PDA

44 Voices of the Board: PDA Working to Harmonize Sterile Manufacturing
46 Editor’s Message: The Intersection of Mainstream and Pharma News
**PDA’s Mission**
To develop scientifically sound, practical technical information and resources to advance science and regulation for the pharmaceutical and biopharmaceutical industry through the expertise of our global membership

**PDA’s Vision**
To be the foremost global provider of science, technology, and regulatory information and education for the pharmaceutical and biopharmaceutical community

---

**Executive Staff**

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Richard Johnson</td>
</tr>
<tr>
<td>CFO</td>
<td>Craig Elliott</td>
</tr>
<tr>
<td>President, PDA Europe</td>
<td>Georg Roessling, PhD</td>
</tr>
<tr>
<td>Sr. VP, Education</td>
<td>Robert Dana</td>
</tr>
<tr>
<td>VP, Sales</td>
<td>David Hall</td>
</tr>
<tr>
<td>Sr. VP, Scientific &amp; Regulatory Affairs</td>
<td>Rich Levy, PhD</td>
</tr>
<tr>
<td>St. Vice President, Programs and Registration Services</td>
<td>Wanda Neal</td>
</tr>
</tbody>
</table>

---

**PDA Board of Directors**

**Chair:** Harold Baseman, ValSource

**Chair-Elect:** Martin VanTrieu, Amgen

**Treasurer:** Rebecca Devine, PhD, Elvins & Associates

**Secretary:** Michael Sadowski, Baxter Healthcare

**Imm. Past Chair:** Anders Vinther, Sanofi Pasteur

**Officers**

- Joyce Bloomfield, Merck
- Ursula Busse, PhD, Novartis
- Jette Christensen, Novo Nordisk
- Ian Elvins, Elvins & Associates
- John Finkbohner, PhD, MedImmune
- Gabriele Gori, Novartis
- Junko Sasaki, Dainippon Sumitomo Pharma
- Lisa Skeens, PhD, Hospira
- Christopher Smalley, PhD, Merck
- Glenn Wright, Eli Lilly and Company

---

**Features**

**30 Proposed USP Chapter on Nonsterile Bioburden Long Overdue But Clarification Still Needed**

USP’s microbiology-related chapters continue to evolve and a new one is wending its way through the pharmacopoeial pathway. The new chapter, with a focus on nonsterile products, is unique and much needed.

**34 Common Areas of Cleanroom Contamination**

This issue’s infographic details areas of a typical cleanroom that often face contamination risks.
Cover

26  Career Advancement Strategies Without the Noise
What hot skills are pharmaceutical and biopharmaceutical companies looking for today? What jobs are most in demand? What do companies want in their quality and regulatory or their manufacturing and process science professionals including those at the Director and Vice President levels? Can you give me some advice on my resume?

Cover Art Illustrated by Katja Yount

Departments

News & Notes

6     PDA In The News

People

8     Volunteer Spotlight: Austin Caudle
10    Chapter Update: India Chapter Addresses Aseptic Concerns, Seeks Solutions
12    Eye on TRI: Aseptic Training Produces Day-to-Day Professional Results
13    PDA Mourns Passing of Solomon C. Pflag
13    PDA Seeking New Volunteers for Upcoming Projects
14    Tools For Success: Chapter Involvement Proves a Worthwhile “Adventure”
16    PDA Pulse: PDA Members Embrace Social Media

Science

18    Science Snapshot: PDA Hosts SUS Workshop with FDA, Other Industry Groups;
      PDA Journal Top 10: PQRI Content Continues to Draw High Readership Levels

18    Particulate Matter Control Key to Preventing 483 Observations
21    Quality Culture Not Just Technological; Skills Key, Too
22    Site Visits Offer PDA Staff View of Industry In Action

Regulation

36    Regulatory Snapshot: RAQAB Update: RAQAB Quarterly Report Q3—New Members and Addressing Compounding cGMPs
38    Quality Metrics: Measuring the Quality Culture
41    Continuing the ICH Q10 Implementation Journey
43    Industry, Regulators Collaborate on ATMPs

Voices of PDA

44    Voices of the Board: Based in Science for the Improvement of our Industry
46    Editor’s Message: Upgrading Skills: A Never-Ending Endeavor
Reduce Human Error in a GMP Facility

Pharmaceutical companies often cite human error as the sole cause of a manufacturing deviation or noncompliance issue. For medical device manufacturers, identifying and reducing the occurrence of human error is commonly part of the regulatory and overall risk management process, but for pharmaceutical facilities, the assessment of human error in the workplace is not always so rigorously assessed during deviation investigations.

Skillsets and Training: Aseptic vs. Solid Dosage Operators

This issue’s infographic shows some of the different training and on-the-job requirements for aseptic vs. sterile dosage operators.
Keeping the Signals Clear: Industry and FDA Collaborate on Innovation

The PDA/FDA Joint Regulatory Conference offers a chance for regulators and members of industry to share information and discuss the pressing issues of the day. This year, two attendees—one with the U.S. FDA and the other with a pharmaceutical company—took the time to share their insights of the conference. Not surprisingly, both noted the spirit of collaboration that marked this year’s joint regulatory conference.

Cover Art Illustrated by Katja Yount
Features

36 Amgen’s Next Gen Manufacturing: A Conversation with Madhu Balachandran

On September 2, the PDA Letter’s Walter Morris interviewed Madhu Balachandran, Executive Vice President, Amgen, Inc. on manufacturing of the future in advance of his presentation at the PDA/FDA Joint Regulatory Conference on September 8. Balachandran answered questions about Amgen’s “Next Generation Manufacturing” facility opening soon in Singapore.

40 Key Takeaways From the 2014 PDA Drug Shortage Workshop

Learn about the latest data on drug shortages in this issue’s infographic which utilizes information presented at this year’s drug shortages workshop.